Si-Yu Yuan, Hai-Bo Yu, Zhen Yang, Yi-Ping Qin, Ji-Hua Ren, Sheng-Tao Cheng, Fang Ren, Betty Yuen Kwan Law, Vincent Kam Wai Wong, Jerome P L Ng, Yu-Jiao Zhou, Xin He, Ming Tan, Zhen-Zhen Zhang, Juan Chen
Current anti-HBV therapeutic strategy relies on interferon and nucleos(t)ide-type drugs with the limitation of functional cure, inducing hepatitis B surface antigen (HBsAg) loss in very few patients. Notably, the level of HBsAg has been established as an accurate indicator to evaluate the drug efficacy and predict the disease prognosis, thus exploring a novel drug targeting HBsAg will be of great significance. Herein, by screening 978 compounds from an FDA-approved drug library and determining the inhibitory function of each drug on HBsAg level in HepG2...
2022: Frontiers in Pharmacology